A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT01200394
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT01200394 -
2010-021358-20
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Denmark, Hong Kong SAR China, India, Malaysia, Mexico, Poland, Serbia, Slovakia, South Africa, South Korea, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01200394. Randomized; double masking; primary purpose treatment. Start 2010-12 (actual); primary completion 2013-07 (actual). Results posted on 2019-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
- Condition
- Diabetic Nephropathies
- Intervention (Drug)
- PF-00489791
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01200394- Content hash
8c6450012a7e4cce207b24310b834a4cbb518b80c6412293436835ba681c3ab3